The estimated Net Worth of Richard Sulpizio is at least $14.5 Milione dollars as of 30 May 2018. Mr. Sulpizio owns over 28,403 units of Resmed stock worth over $9,060,353 and over the last 19 years he sold RMD stock worth over $5,127,326. In addition, he makes $330,052 as Independent Director at Resmed.
Richard has made over 11 trades of the Resmed stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 28,403 units of RMD stock worth $783,355 on 30 May 2018.
The largest trade he's ever made was exercising 72,000 units of Resmed stock on 4 February 2015 worth over $1,296,720. On average, Richard trades about 9,132 units every 100 days since 2005. As of 30 May 2018 he still owns at least 35,823 units of Resmed stock.
You can see the complete history of Mr. Sulpizio stock trades at the bottom of the page.
Richard Sulpizio serves as Independent Director of the Company. Mr. Sulpizio retired as president and chief operating officer of Qualcomm, Inc. (NASDAQ: QCOM) in 2001. He served on Qualcomm’s board of directors from 2000 until 2007. Mr. Sulpizio joined Qualcomm in 1991 and in 1994, was appointed president of Qualcomm Wireless Business Solutions. Four years later, he became Qualcomm’s president and COO. In 2002, he rejoined Qualcomm to serve as interim president of Qualcomm China and then took the helm of Qualcomm Europe in 2004. He was appointed as president in 2005 of MediaFLO USA, Inc. a wholly-owned subsidiary of Qualcomm, and was chartered with overseeing the development and deployment of MediaFLO technology and bringing multimedia services to the wireless industry. His last assignment, from December 2009 to November 2013, was president and CEO of Qualcomm Enterprise Services (QES), which was sold to a private equity firm. Before joining Qualcomm, Mr. Sulpizio worked at Unisys Corporation (NYSE: UIS) and Fluor Corporation (NYSE: FLR). From 2009 through 2018, Mr. Sulpizio served as a director of CA, Inc. (NASDAQ: CA), an information technology management software company. He currently serves as an honorary board member of the advisory board of the University of California San Diego’s Sulpizio Family Cardiovascular Center. He holds a bachelor of arts from California State University, Los Angeles, and a master of science in systems management from the University of Southern California. Mr. Sulpizio’s experience and skills, particularly his experience with high growth technology companies, executive and board experience with software businesses, and international business experience led the board to the conclusion that he should serve as a director.
As the Independent Director of Resmed, the total compensation of Richard Sulpizio at Resmed is $330,052. There are 16 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.
Richard Sulpizio is 70, he's been the Independent Director of Resmed since 2005. There are 4 older and 18 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Richard's mailing address filed with the SEC is RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123.
Over the last 23 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace e David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: